All In Biotech

Drug Trial Radar · NCT07859202

The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505.

A Prospective, Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of W2505

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

228

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
GL Pharm Tech CorporationIndustry
Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of W2505.

Conditions

  • Erectile Dysfunctions

Interventions

  • W2505Drug

    PO, Once daily(QD), 12 weeks

  • W2505-P1Drug

    PO, Once daily(QD), 12 weeks

  • W2505-RDrug

    PO, Once daily(QD), 12 weeks

  • W2505-P2Drug

    PO, Once daily(QD), 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain ScoreTime frame: Baseline, Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Inha University Hospital

    Incheon, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.